AnaptysBio (ANAB)
(Delayed Data from NSDQ)
$37.53 USD
+0.96 (2.63%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $37.45 -0.08 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for AnaptysBio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 391 | 441 | 548 | 394 | 374 |
Receivables | 7 | 1 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 5 | 5 | 3 | 4 |
Total Current Assets | 407 | 447 | 554 | 397 | 378 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 27 | 143 | 67 | 18 | 54 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 1 | 2 |
Total Assets | 452 | 610 | 643 | 417 | 435 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 1 |
Accounts Payable | 5 | 3 | 2 | 4 | 16 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 31 | 22 | 13 | 15 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 2 | 0 | 1 |
Total Current Liabilities | 37 | 26 | 16 | 20 | 30 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 311 | 304 | 251 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 364 | 348 | 287 | 20 | 30 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 703 | 718 | 679 | 661 | 649 |
Retained Earnings | -614 | -450 | -322 | -264 | -244 |
Other Equity | -1 | -5 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 88 | 262 | 356 | 397 | 405 |
Total Liabilities & Shareholder's Equity | 452 | 610 | 643 | 417 | 435 |
Total Common Equity | 88 | 262 | 356 | 397 | 405 |
Shares Outstanding | 26.50 | 28.40 | 27.60 | 27.30 | 27.10 |
Book Value Per Share | 3.32 | 9.23 | 12.91 | 14.53 | 14.95 |
Fiscal Year End for AnaptysBio, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 351 | 355 | 391 | 413 | 429 |
Receivables | 9 | 7 | 7 | 3 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 11 | 9 | 12 | 6 |
Total Current Assets | 367 | 372 | 407 | 428 | 439 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 43 | 15 | 27 | 40 | 59 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 427 | 406 | 452 | 487 | 517 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 5 | 7 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 34 | 26 | 31 | 31 | 35 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 40 | 32 | 37 | 39 | 42 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 362 | 311 | 311 | 310 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 418 | 358 | 364 | 367 | 369 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 715 | 706 | 703 | 695 | 687 |
Retained Earnings | -705 | -658 | -614 | -572 | -535 |
Other Equity | 0 | -1 | -1 | -2 | -4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 10 | 48 | 88 | 120 | 148 |
Total Liabilities & Shareholder's Equity | 427 | 406 | 452 | 487 | 517 |
Total Common Equity | 10 | 48 | 88 | 120 | 148 |
Shares Outstanding | 27.30 | 27.30 | 26.50 | 26.50 | 26.40 |
Book Value Per Share | 0.36 | 1.75 | 3.32 | 4.54 | 5.62 |